Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord ID
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.body massRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days7CMO:0001400maximum body weight loss to initial body weight ratio0%0.00.0MMO:0000016body weighing method0.0from before p.i.intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68728myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.body massRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days8CMO:0001400maximum body weight loss to initial body weight ratio0%0.00.0MMO:0000016body weighing method0.0from before p.i.intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68725myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.body massRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days10CMO:0001400maximum body weight loss to initial body weight ratio0%0.00.0MMO:0000016body weighing method0.0from before p.i.intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68723myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.body massRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days10CMO:0001400maximum body weight loss to initial body weight ratio1.2%1.13843.6MMO:0000016body weighing method0.0from before p.i.intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68720myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days1CMO:0001402percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time0%MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68729myelin oligodendrocyte glycoprotein (20 ug)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days7CMO:0001402percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time0%MMO:0000163in vivo visual assessmentwhole animal0.0range 31 to 40 daysinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68733myelin oligodendrocyte glycoprotein (200 ul)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days8CMO:0001402percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time37.5%MMO:0000163in vivo visual assessmentwhole animal0.0range 31 to 40 daysinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68732myelin oligodendrocyte glycoprotein (200 ul)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days3CMO:0001402percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time0%MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68721myelin oligodendrocyte glycoprotein (20 ug)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days6CMO:0001422post-insult time to onset of experimental autoimmune encephalomyelitis13.3d2.66.3687MMO:0000163in vivo visual assessmentwhole animal0.0range 31 to 40 daysinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68731myelin oligodendrocyte glycoprotein (200 ul)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days1CMO:0001422post-insult time to onset of experimental autoimmune encephalomyelitis3d0.00.0MMO:0000163in vivo visual assessmentwhole animal0.0range 31 to 40 daysinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68730myelin oligodendrocyte glycoprotein (200 ul)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days1CMO:0001422post-insult time to onset of experimental autoimmune encephalomyelitis23dMMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injectionmyelin oligodendrocyte glycoprotein (20 ug) 68727myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days3CMO:0001422post-insult time to onset of experimental autoimmune encephalomyelitis14.7d1.44342.5MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injectionmyelin oligodendrocyte glycoprotein (20 ug) 68719myelin oligodendrocyte glycoprotein (20 ug)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.total life spanRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days8CMO:0001024percentage of deaths in a study population during a period of time12.5%MMO:0000344necropsywhole animal0.0visual assessmentinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68737myelin oligodendrocyte glycoprotein (200 ul)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.total life spanRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days7CMO:0001024percentage of deaths in a study population during a period of time0%MMO:0000344necropsywhole animal0.0visual assessmentinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68736myelin oligodendrocyte glycoprotein (200 ul)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days8CMO:0001047percentage of study population developing experimental autoimmune encephalomyelitis during a period of time75%MMO:0000163in vivo visual assessmentwhole animal0.0range 31 to 40 daysinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68735myelin oligodendrocyte glycoprotein (200 ul)
829Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kininot specified105 days to 63 days7CMO:0001047percentage of study population developing experimental autoimmune encephalomyelitis during a period of time14.3%MMO:0000163in vivo visual assessmentwhole animal0.0range 31 to 40 daysinjection40daysmyelin oligodendrocyte glycoprotein (200 ul) 68734myelin oligodendrocyte glycoprotein (200 ul)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days7CMO:0001047percentage of study population developing experimental autoimmune encephalomyelitis during a period of time14%MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68726myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days8CMO:0001047percentage of study population developing experimental autoimmune encephalomyelitis during a period of time0%MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68724myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days10CMO:0001047percentage of study population developing experimental autoimmune encephalomyelitis during a period of time0%MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68722myelin oligodendrocyte glycoprotein (20 ug)
839Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.central nervous system integrity traitRS:0000199DA.ACI-(D10Rat2-D10Rat29)/Kinimale131 days to 103 days10CMO:0001047percentage of study population developing experimental autoimmune encephalomyelitis during a period of time30%MMO:0000163in vivo visual assessment0.0from p.i. day 7intradermal injection40daysmyelin oligodendrocyte glycoprotein (20 ug) 68718myelin oligodendrocyte glycoprotein (20 ug)